The nuclear receptor subfamily 2 group C member 2 (NR2C2), also known as testicular receptor 4 (TR4), is a transcription factor belonging to the nuclear receptor superfamily. It plays diverse roles in regulating gene expression by binding to specific DNA response elements, either as a monomer, homodimer, or heterodimer with other receptors. NR2C2 is involved in critical biological processes, including embryonic development, metabolism, reproduction, and circadian rhythm regulation. Studies highlight its function in lipid metabolism, glucose homeostasis, and adipocyte differentiation, linking it to metabolic disorders like obesity and diabetes. Additionally, NR2C2 has been implicated in cancer progression, with both tumor-suppressive and oncogenic roles observed in different contexts, such as prostate, liver, and colorectal cancers.
NR2C2 antibodies are essential tools for investigating its expression, localization, and molecular interactions in research. They are widely used in techniques like Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP) to study NR2C2's regulatory mechanisms in health and disease. Commercially available antibodies are typically raised against specific epitopes, such as the N-terminal or ligand-binding domains, and require validation for specificity and cross-reactivity. Research utilizing NR2C2 antibodies continues to uncover its therapeutic potential, particularly in targeting metabolic syndromes and cancers, though its context-dependent roles necessitate careful functional analysis in different tissues and pathological conditions.